Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15

Benzinga Newsdesk www.benzinga.com Positive 75.2%

Neg 0% Neu 0% Pos 75.2%

Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the price target from $13 to $15.